glp 1 agonist drugs for weight loss GLP-1s Loss: What You Need to Know GLP-1 Drug Savings: A Complete

10 A small retrospective observational study found that participants on the ketogenic diet had a reduction in monthly migraine days along with reduced body weight and BMI

doi: 10.1161/CIRCULATIONAHA.112.091215

dosage should be reduced in patients with renal impairment no dosage adjustment required for mild to moderate hepatic insufficiency Side Effects: upper respiratory infection pancreatitis - there have been post-marketing reports of acute pancreatitis

Case reports of transgender patients undergoing female to male gender reassignment provide important insights into the role of androgens in IIH

Safety Considerations and Future Outlook As with all pharmacotherapy for obesity and T2D, establishing cardiovascular safety and demonstrating improvements in meaningful clinical outcomes will be essential, particularly as cardiovascular outcome trials have not yet been completed with multi-agonists (although data are expected soon for tirzepatide: SURPASS-CVOT [T2D] in 2025

Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes